
PALI · NASDAQ
Palisade Bio, Inc.
$1.17 -0.03 (-2.09%)
Company overview
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of a digestive enzyme inhibitor intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $204M
- Employees
- 8
- Headquarters
- Carlsbad, CA
- Website
- palisadebio.com
- CEO
- J. D. Finley
- Listed
- March 30, 2007
- P/E
- -1.10
- Dividend yield
- 0.00%
Company financials
- Revenue
- $0.00
- Gross profit
- $0.00
- Operating income
- -$26.5M
- EBITDA
- -$26.6M
- Net income
- -$24.2M
- EPS
- -$1.06
- Total assets
- $133M
- Total debt
- $0.00
- Earnings yield
- -90.74%
No annual segmentation.
No geographic segmentation.
News
| Ticker | Type | Headline | Source | Published |
|---|---|---|---|---|
Loading headlines… | ||||